Melatonin May Increase Anticancer Potential of Pleiotropic Drugs
AbstractMelatonin (N-acetyl-5-methoxytryptamine) is not only a pineal hormone, but also an ubiquitary molecule present in plants and part of our diet. Numerous preclinical and some clinical reports pointed to its multiple beneficial effects including oncostatic properties, and as such, it has become one of the most aspiring goals in cancer prevention/therapy. A link between cancer and inflammation and/or metabolic disorders has been well established and the therapy of these conditions with so-called pleiotropic drugs, which include non-steroidal anti-inflammatory drugs, statins and peroral antidiabetics, modulates a cancer risk too. Adjuvant therapy with melatonin may improve the oncostatic potential of these drugs. Results from preclinical studies are limited though support this hypothesis, which, however, remains to be verified by further research. View Full-Text
- Supplementary File 1:
PDF-Document (PDF, 110 KB)
Share & Cite This Article
Bojková, B.; Kubatka, P.; Qaradakhi, T.; Zulli, A.; Kajo, K. Melatonin May Increase Anticancer Potential of Pleiotropic Drugs. Int. J. Mol. Sci. 2018, 19, 3910.
Bojková B, Kubatka P, Qaradakhi T, Zulli A, Kajo K. Melatonin May Increase Anticancer Potential of Pleiotropic Drugs. International Journal of Molecular Sciences. 2018; 19(12):3910.Chicago/Turabian Style
Bojková, Bianka; Kubatka, Peter; Qaradakhi, Tawar; Zulli, Anthony; Kajo, Karol. 2018. "Melatonin May Increase Anticancer Potential of Pleiotropic Drugs." Int. J. Mol. Sci. 19, no. 12: 3910.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.